Jefferies Financial Group Inc. Has $6.24 Million Holdings in Nkarta, Inc. (NASDAQ:NKTX)

Jefferies Financial Group Inc. boosted its stake in Nkarta, Inc. (NASDAQ:NKTX) by 901.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 2,504,219 shares of the company’s stock after buying an additional 2,254,219 shares during the period. Jefferies Financial Group Inc.’s holdings in Nkarta were worth $6,236,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. JPMorgan Chase & Co. increased its holdings in Nkarta by 138.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company’s stock valued at $6,319,000 after purchasing an additional 1,474,560 shares during the period. Wasatch Advisors LP grew its stake in shares of Nkarta by 37.4% in the 4th quarter. Wasatch Advisors LP now owns 2,520,909 shares of the company’s stock valued at $6,277,000 after buying an additional 686,229 shares during the period. Alyeska Investment Group L.P. grew its stake in shares of Nkarta by 23.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,334,696 shares of the company’s stock valued at $3,323,000 after buying an additional 250,000 shares during the period. Geode Capital Management LLC grew its stake in shares of Nkarta by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,181,357 shares of the company’s stock valued at $2,942,000 after buying an additional 10,331 shares during the period. Finally, Affinity Asset Advisors LLC lifted its position in Nkarta by 23.1% in the 4th quarter. Affinity Asset Advisors LLC now owns 800,000 shares of the company’s stock valued at $1,992,000 after acquiring an additional 150,000 shares in the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Stock Down 0.3%

NASDAQ NKTX opened at $1.95 on Monday. The stock’s 50-day simple moving average is $1.78 and its two-hundred day simple moving average is $2.24. Nkarta, Inc. has a twelve month low of $1.31 and a twelve month high of $8.23. The company has a market capitalization of $138.01 million, a price-to-earnings ratio of -1.03 and a beta of 0.81.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. On average, equities analysts expect that Nkarta, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on NKTX. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Nkarta in a research note on Thursday, March 27th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Nkarta in a research note on Wednesday, April 9th. Finally, Stifel Nicolaus cut their price target on Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 27th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $14.83.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.